Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model.
about
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNSPharmacometabolomic signature of ataxia SCA1 mouse model and lithium effectsClarifying lysosomal storage diseasesTherapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorderThe role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesisGene, Stem Cell, and Alternative Therapies for SCA 1A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium saltsMouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.No benefit from chronic lithium dosing in a sibling-matched, gender balanced, investigator-blinded trial using a standard mouse model of familial ALSTherapeutic prospects for spinocerebellar ataxia type 2 and 3.Hyperactivity, startle reactivity and cell-proliferation deficits are resistant to chronic lithium treatment in adult Nr2e1(frc/frc) miceThe neurotrophic and neuroprotective effects of psychotropic agents.Imbalanced pattern completion vs. separation in cognitive disease: network simulations of synaptic pathologies predict a personalized therapeutics strategy.Alterations in molecular chaperones and eIF2alpha during lung endothelial cell apoptosisThe histone deacetylase HDAC3 is essential for Purkinje cell function, potentially complicating the use of HDAC inhibitors in SCA1Dopamine D2 receptor signaling modulates mutant ataxin-1 S776 phosphorylation and aggregation.Milestones in ataxiaBroad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapyHomozygous splice mutation in CWF19L1 in a Turkish family with recessive ataxia syndromeHMGB1 facilitates repair of mitochondrial DNA damage and extends the lifespan of mutant ataxin-1 knock-in mice.Consensus paper: management of degenerative cerebellar disorders.Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disordersThe transcription factor SP4 is reduced in postmortem cerebellum of bipolar disorder subjects: control by depolarization and lithium.Inhibition of GSK3β improves hippocampus-dependent learning and rescues neurogenesis in a mouse model of fragile X syndromeLoss of MyD88 alters neuroinflammatory response and attenuates early Purkinje cell loss in a spinocerebellar ataxia type 6 mouse modelNeuroprotective effect of lithium after pilocarpine-induced status epilepticus in mice.Abnormalities in synaptic dynamics during development in a mouse model of spinocerebellar ataxia type 1.Rapid Onset of Motor Deficits in a Mouse Model of Spinocerebellar Ataxia Type 6 Precedes Late Cerebellar DegenerationMutation in ATG5 reduces autophagy and leads to ataxia with developmental delay.Spinocerebellar ataxia type 6 knockin mice develop a progressive neuronal dysfunction with age-dependent accumulation of mutant CaV2.1 channels.The role of GSK-3 in synaptic plasticity.Spinocerebellar ataxia type 2 presenting with cognitive regression in childhood.Pharmacogenetic analysis of lithium-induced delayed aging in Caenorhabditis elegans.Non-invasive measurement of cerebral oxygen metabolism in the mouse brain by ultra-high field (17)O MR spectroscopy.Lithium in neuropsychiatry: a 2010 update.Genetically engineered mouse models of the trinucleotide-repeat spinocerebellar ataxias.Lithium's role in neural plasticity and its implications for mood disordersGlycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments.Polyglutamine (PolyQ) diseases: genetics to treatments.Mutational consequences of aberrant ion channels in neurological disorders.
P2860
Q21129334-8307088A-F4C3-4721-8F22-664A69F7C788Q21559578-7A85DE27-3771-4618-8D43-DCA0E9FDBF99Q24620532-962EB824-E614-4112-8966-8201EECD0F8DQ24626017-A5797F4F-E4D2-4B51-A2F8-F59B4F114874Q24651407-81E332CE-8E1A-43C2-9E5E-6E4B8B8EA835Q26738497-FBCB11BA-CBEF-456E-A4BE-0C9D9B915185Q26741164-61C7C019-5A4F-457D-B9A5-CB25A6C2372AQ27005950-03A33749-3DB4-4D69-ADCA-5E10D02C447AQ27345515-537B973F-2CCF-42F8-8616-764C1947FB3CQ30410969-47086EEF-C5D2-42F1-BA6B-953ECC206400Q30469863-7B4AD36D-9CAB-4412-936D-2236AA0FE0FDQ33583992-C4C2358B-D1B0-4102-8761-1CB19496DA7FQ33655637-01D5DDED-B39E-4795-A7A4-D7988B2AA161Q33784115-04B9A07C-32CC-44D7-ACBA-62EBB98C12AAQ33784471-31DE9549-22F1-4315-BDAD-33CC3973549AQ34066247-5B7D8729-C0F3-43A2-94D1-BF4FCDF02A77Q34188468-5B383DB9-FC98-4F30-90BF-54D878CE4F15Q34397572-29B2E920-9E70-4627-ABC5-396BD5920079Q34771211-09ABCE2C-4654-4F20-BB84-57C38D28F6D7Q35023867-C54AD43E-56FC-42C2-801E-40EB25F1AE1AQ35129909-116EF66C-0FF5-4BCA-BD68-799DFC64C44AQ35197096-7275D961-D6F5-439E-9DFE-50719A101F26Q35451948-809E932C-E222-419C-9FF4-EE83CE000312Q35674710-A6661E9E-86DA-4AE8-9FA5-617293C5B63EQ35924050-B2A53896-932D-46D7-AC29-CE3EBDCF08E9Q36244032-97EF4AA6-F7F5-4700-AF1A-95083E45A4DEQ36245783-81886E46-762C-4D63-9011-02D178EF4337Q36419060-DAAB00C0-A91E-4B01-8575-F0DD50F99F04Q36673666-AA85325A-FA4C-4038-941B-612C0B492252Q36823235-3BD400FE-5980-49D5-817D-BED238DE6A21Q37098587-397BF4BC-6B83-4FAA-AE16-02B739626F26Q37216544-9636BD26-A287-4DF5-8F38-2DC073DA7CAAQ37337188-91814303-7CE4-4432-9771-28677ED6E3D6Q37365662-91FBFBC6-E70C-4E7C-8839-442646C8ED99Q37848442-3548E110-4663-41CF-B948-05385866DE7AQ37910368-D5CECF3C-1944-440A-BCC4-B9ADEBECE9E3Q38101644-784642F6-8B57-447E-AED3-C48D16DE5A3EQ38126701-8D94B379-B873-4511-972C-2E3EC7E9A951Q38210865-0655A977-E3D3-4C25-BE8B-7AEE3A510444Q38239544-DB85696E-BEC5-4E3C-AC80-2AE4A073221B
P2860
Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Lithium therapy improves neuro ...... llar ataxia type 1 mouse model
@nl
Lithium therapy improves neuro ...... lar ataxia type 1 mouse model.
@ast
Lithium therapy improves neuro ...... lar ataxia type 1 mouse model.
@en
type
label
Lithium therapy improves neuro ...... llar ataxia type 1 mouse model
@nl
Lithium therapy improves neuro ...... lar ataxia type 1 mouse model.
@ast
Lithium therapy improves neuro ...... lar ataxia type 1 mouse model.
@en
altLabel
Lithium therapy improves neuro ...... llar ataxia type 1 mouse model
@en
prefLabel
Lithium therapy improves neuro ...... llar ataxia type 1 mouse model
@nl
Lithium therapy improves neuro ...... lar ataxia type 1 mouse model.
@ast
Lithium therapy improves neuro ...... lar ataxia type 1 mouse model.
@en
P2093
P2860
P50
P3181
P1433
P1476
Lithium therapy improves neuro ...... lar ataxia type 1 mouse model.
@en
P2093
Effat Emamian
Hidehiro Mizusawa
Kei Watase
Richard Atkinson
Ronald Richman
Yaling Sun
P2860
P3181
P356
10.1371/JOURNAL.PMED.0040182
P407
P577
2007-05-01T00:00:00Z